by Barry101 | Aug 28, 2018 | Press Release
ORLANDO, Fla., Aug. 28, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released for patients’ use in the pancreatic cancer Early Access Program (EAP) in the...
by Barry101 | Aug 24, 2018 | Press Release
ORLANDO, Fla., Aug. 24, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it will be presenting at the 20th Annual Rodman...
by Barry101 | Aug 24, 2018 | Press Release
ORLANDO, Fla., Aug. 24, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it will be presenting at the 20th Annual Rodman...
by Barry101 | Aug 15, 2018 | Press Release
OCALA, Fla., Aug. 15, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, has announced its financial results for the six months ended June 30,...
by Barry101 | Aug 13, 2018 | Press Release
OCALA, Fla., Aug. 13, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, is pleased to announce it mailed a letter to stockholders on August 11,...
by Barry101 | Jul 9, 2018 | Press Release
ORLANDO, Fla., July 09, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen® in combination with FluMist® influenza vaccine with the U.S. Food and...
